Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dillner Joakim) "

Sökning: WFRF:(Dillner Joakim)

Sortera/gruppera träfflistan
  • Bjerre, P., et al. (författare)
  • A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage
  • 2008
  • Ingår i: American Journal of Obstetrics and Gynecology. - : Elsevier. - 1097-6868 .- 0002-9378. ; 199:1, s. 24 e1-7
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: This study was undertaken to compare management algorithms that base treatment with loop electrosurgical excision procedure on human papillomavirus and/or repeat Papanicolaou test smear results. STUDY DESIGN: A randomized trial that referred 674 women with either atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions cytology results, detected in organized screening to treatment either (1) if they were positive in a repeat Papanicolaou test smear and/or a human papillomavirus test or (2) if they were positive in the repeat Papanicolaou test smear test only. Women who tested positive were treated, regardless of colposcopic findings. RESULTS: There were 208 of 337 (62%) women who were treated in the human papillomavirus /Papanicolaou test smear group (187/337 because of HPV positivity) and 138 of 337 (41%) in the Papanicolaou test smear only group. Histopathologically diagnosed cervical intraepithelial neoplasia grade 2 or worse was found among 112 of 337 (33.2%) women in the human papillomavirus/Papanicolaou test smear group compared with 85 of 337 (25.2%) women in the Papanicolaou test smear only group (P < .05). Twenty-one women with cervical intraepithelial neoplasia 2+ had normal colposcopy. CONCLUSION: For adequate cervical intraepithelial neoplasia 2+ sensitivity, the decision to use loop electrosurgical excision procedure needs to be based on human papillomavirus testing results and should not exclude women with normal colposcopy.
  • Dillner, Joakim, et al. (författare)
  • Monitoring of human papillomavirus vaccination.
  • 2011
  • Ingår i: Clinical and Experimental Immunology. - : British Society for Immunology. - 0009-9104. ; 163:1, s. 17-25
  • Tidskriftsartikel (refereegranskat)abstract
    • Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.
  • Dillner, Lena, et al. (författare)
  • Randomized healthservices study of human papillomavirus-based management of low-grade cytological abnormalities.
  • 2011
  • Ingår i: International Journal of Cancer. - : John Wiley and Sons. - 0020-7136. ; 129:1, s. 151-159
  • Tidskriftsartikel (refereegranskat)abstract
    • Human Papillomavirus (HPV)-based management of women with borderline (ASCUS) or mildly abnormal (CINI) cervical cytology has been extensively studied in the research setting. We wished to assess safety and healthcare resource use of a real-life healthcare policy using HPV triaging.All 15 outpatient clinics involved in the organized population-based screening program in Stockholm, Sweden screening program were randomized to either continue with prior policy (colposcopy of all women with ASCUS/CINI) or to implement a policy with HPV triaging and colposcopy only of HPV-positive women. The trial enrolled the 3319 women that were diagnosed with ASCUS (n=1335) or CINI (n=1984) in Stockholm during 17(th) March 2003 to 16(th) January 2006. Detection of high-grade cervical lesions (CINII+) and health care cost consumption was studied by registry linkages.The proportion of histopathology-verified CINII+ was similar for the 2 policies (395/1752 women (22.5%; 95% Confidence interval (CI): 20,6-24,6%) had CINII+ diagnosed with HPV triaging policy, 318/1567 women (20.3%; 95%CI: 18,3-22,4%)) had CINII+ with colposcopy policy). 64% of women with ASCUS and 77% of women with CINI were HPV-positive. HPV-positivity was age-dependent, with 81% of women below 35 years of age and 44% of women above 45 years of age testing HPV-positive. HPV triaging was cost-effective only above 35 years of age.In conclusion, a real-life randomised healthservices study of HPV triaging of women with ASCUS/CINI demonstrated similar detection of CINII+ as colposcopy of all women.
  • Dillner, Lena, et al. (författare)
  • Strengthening prevention programs to eliminate cervical cancer in the Nordic countries.
  • 2008
  • Ingår i: Acta Obstetricia et Gynecologica Scandinavica. - : Wiley-Blackwell. - 1600-0412. ; 87:5, s. 489-498
  • Forskningsöversikt (refereegranskat)abstract
    • Disease trend studies based on birth cohort analysis and serological studies indicate that recent generations have a higher prevalence of oncogenic Human Papilloma Virus (HPV) types, and are likely to be at higher risk of cancer than previous generations. This implies that prevention strategies to protect young populations from HPV-associated cancers need to be strengthened, and hence organized implementation of vaccination and better screening programs are being considered. In this context, randomized large-scale policy evaluations will be instrumental in accelerating disease control and improve effective prevention programs. This report shares experiences from Nordic countries with examples of prevention strategies through vaccination and cervical screening. The same principles as set up for organized programs and new HPV technologies may apply for screening and vaccination as key tools to eliminate cervical cancer in the Nordic countries and globally.
  • Persson, Kenneth, et al. (författare)
  • Decline of the new Swedish variant of Chlamydia trachomatis after introduction of appropriate testing.
  • 2012
  • Ingår i: Sexually Transmitted Infections. - : BMJ Publishing Group. - 1368-4973 .- 1472-3263. ; 88:6, s. 81-451
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: The longitudinal epidemiological development of the new variant of Chlamydia trachomatis was studied after appropriate testing procedures had been introduced when the strain was detected in 2006. Methods: The number of cases of the new variant of C trachomatis was followed from 2007 through 2011 from the laboratory records. Testing for C trachomatis is centralised to one laboratory with around 80-85 000 persons being tested annually in a population of 1.1 million. Results: During the 5-year period, 410 973 patients were tested of which 25 723 cases were positive. The proportion of the new variant of all positive cases declined from 30% in 2007 to 6% in 2011. While the number of the new variant of C trachomatis declined, the ordinary wild-type strains remained largely unchanged. Conclusions: A selective decline of the new variant of C trachomatis has occurred after appropriate laboratory testing was introduced. A new balance point between 5% and 10% for the new variant seems to be gradually approached.
  • Söderlund Strand, Anna, et al. (författare)
  • Genotyping of human papillomavirus in triaging of low-grade cervical cytology.
  • 2011
  • Ingår i: American Journal of Obstetrics and Gynecology. - : Elsevier. - 1097-6868. ; 205:2, s. 1-145
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The objective of the study was to evaluate whether typing of human papillomavirus (HPV) among women with low-grade cervical cytology can improve the ability to identify women with cervical cancer or cervical intraepithelial neoplasia grade III (CIN III or worse). STUDY DESIGN: A total of 1595 women with low-grade cervical cytology participating in a randomized implementation trial of HPV triaging using Hybrid Capture II were also HPV genotyped and CIN III or worse predictive values evaluated. RESULTS: HPV 16 was detected in 57% of cases with CIN III or worse but only among 24% of all tested women. Testing for the 3 HPV types with highest risk (HPV16/31/33) detected 77% of CIN III or worse, with 36% of women testing positive. Positivity for the other high-risk HPV types had a decreased risk for CIN III or worse. CONCLUSION: Different high-risk HPV types confer different risks for the presence of CIN III or worse, implying that HPV genotyping could be useful for the optimization of triaging strategies.
  • Wahlström, Cecilia, et al. (författare)
  • Population-based study of screening test performance indices of three human papillomavirus DNA tests
  • 2007
  • Ingår i: Journal of Medical Virology. - : John Wiley and Sons. - 1096-9071 .- 0146-6615. ; 79:8, s. 1169-1175
  • Tidskriftsartikel (refereegranskat)abstract
    • In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical intraepithelial neoplasia grade 2 or worse (CINII+), and absolute risk of CINII+ was 7.1%, 87.1%, and 23.2% for AmpliTaq GP5+/6+ PCR, 11.9%, 88.9%, and 11.0% for AmpliTaq Gold GP5+/6+ PCR, 15.7%, 93.4%, and 9.8% for Amplicor, 10.0%, 92.9%, and 15.3% for Amplicor with raised cut-off, and 7.8%, 79.7%, and 16.9% for Hybrid Capture II. In conclusion, AmpliTaq GP5+/6+ PCR and Amplicor with raised cut-off value have adequate performance indices for primary screening.
  • Bistoletti, P., et al. (författare)
  • Cost-effectiveness of primary cytology and HPV DNA cervical screening
  • 2008
  • Ingår i: International Journal of Cancer. - : John Wiley and Sons. - 0020-7136 .- 1097-0215. ; 122:2, s. 372-376
  • Tidskriftsartikel (refereegranskat)abstract
    • Because cost-effectiveness of different cervical cytology screening strategies with and without human papillomavirus (HPV) DNA testing is unclear, we used a Markov model to estimate life expectancy and health care cost per woman during the remaining lifetime for 4 screening strategies: (i) cervical cytology screening at age 32, 35, 38, 41, 44, 47, 50, 55 and 60, (ii) same strategy with addition of testing for HPV DNA persistence at age 32, (iii) screening with combined cytology and testing for HPV DNA persistence at age 32, 41 and 50, iv) no screening. Input data were derived from population-based screening registries, health-service costs and from a population-based HPV screening trial. Impact of parameter uncertainty was addressed using probabilistic multivariate sensitivity analysis. Cytology screening between 32 and 60 years of age in 3-5 year intervals increased life expectancy and life-time costs were reduced from 533 to 248 US Dollars per woman compared to no screening. Addition of HPV DNA testing, at age 32 increased costs from 248 to 284 US Dollars without benefit on life expectancy. Screening with both cytology and HPV DNA testing, at ages 32, 41 and 50 reduced costs from 248 to 210 US Dollars with slightly increased life expectancy. In conclusion, population-based, organized cervical cytology screening between ages 32 to 60 is highly cost-efficient for cervical cancer prevention. If screening intervals are increased to at least 9 years, combined cytology and HPV DNA screening appeared to be still more effective and less costly. © 2007 Wiley-Liss, Inc.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (248)
konferensbidrag (8)
forskningsöversikt (8)
bokkapitel (4)
annan publikation (2)
Typ av innehåll
refereegranskat (258)
övrigt vetenskapligt (12)
Dillner, Joakim (270)
Dillner, J (232)
Forslund, Ola (46)
Lehtinen, M (43)
Forslund, O (43)
Lehtinen, Matti (38)
visa fler...
Sparen, P (29)
Hallmans, G (24)
Luostarinen, T (22)
Sparén, Pär (22)
Eklund, C (21)
Koskela, P (21)
Hallmans, Göran (21)
Paavonen, J (20)
Ekström, Johanna (20)
Eklund, Carina (20)
Luostarinen, Tapio (19)
Ekstrom, J (18)
Wadell, G (16)
Bzhalava, D (16)
Paavonen, Jorma (16)
Bzhalava, Davit (15)
Bosch, FX (15)
Wadell, Göran (14)
Andersson, Kristin (14)
Hakama, M (14)
Thoresen, S (14)
Munoz, N (14)
Faust, Helena (14)
Stattin, P (13)
Arbyn, M (13)
Ploner, Alexander (13)
Andrae, B. (13)
Andrae, Bengt (13)
Jellum, E (13)
Lagheden, C (13)
Bosch, F. Xavier (13)
Sigurdsson, K (13)
Majewski, S. (12)
Pukkala, E (12)
Sundstrom, K (12)
Sundström, Karin (12)
Ploner, A (12)
Söderlund Strand, An ... (12)
Hakama, Matti (12)
Hultin, E (12)
Lagheden, Camilla (12)
Carlson, Joyce (12)
Kjaer, SK (12)
Elfstrom, KM (12)
visa färre...
Lunds universitet (228)
Karolinska Institutet (178)
Umeå universitet (46)
Uppsala universitet (21)
Göteborgs universitet (16)
Linköpings universitet (6)
visa fler...
Kungliga Tekniska Högskolan (4)
Stockholms universitet (1)
Örebro universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Engelska (262)
Svenska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (256)
Naturvetenskap (10)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy